Newpace

Company Overview

Snapshot

Founded in October 2012 by Avi Broder, Newpace operates with 1–10 employees. The company has raised $2 million across two funding rounds from two investors. In June 2021, Newpace partnered with Powermat Technologies to develop advanced wireless charging technology for its life-saving devices.

Business overview

Newpace is a Health Tech & Life Sciences company focused on developing a flexible and subcutaneous implantable cardioverter defibrillator (ICD). This device differentiates itself from standard ICDs by eliminating leads within the heart, featuring a wireless rechargeable battery, and enabling Bluetooth communication. The company's product, the Implantable String Subcutaneous Defibrillator (ISSD), is designed for subcutaneous implantation without the need for fluoroscopy and requires minimal annual recharging. Newpace serves the healthcare market, specifically targeting patients and providers in the cardiology and medical device sectors.

Strategic signal

In June 2021, Newpace announced a strategic partnership with Powermat Technologies to integrate advanced wireless charging technology into its innovative life-saving devices. This collaboration is significant as it aims to enhance the user experience for patients by reducing battery size and offering a more comfortable charging solution. For investors, this signals Newpace's commitment to product innovation and patient-centric design, potentially accelerating market adoption and strengthening its competitive position in the medical device sector.

Company Intelligence Q&A

What is Newpace's core product?

Newpace develops a flexible and subcutaneous implantable cardioverter defibrillator (ICD) with no leads within the heart, featuring a wireless rechargeable battery and Bluetooth communication. This device is known as the Implantable String Subcutaneous Defibrillator (ISSD).

When was Newpace founded and by whom?

Newpace was founded in October 2012 by Avi Broder.

What was a key partnership announced by Newpace in 2021?

In June 2021, Newpace selected Powermat Technologies to develop advanced wireless charging technology for its innovative life-saving devices.

What was the outcome of the feasibility study for Newpace's ISSD?

A feasibility study on Newpace's novel implantable string subcutaneous defibrillator (ISSD), presented in June 2017, showed that the device successfully defibrillated patients and had a fast implantation time, indicating its potential as a less invasive alternative to current subcutaneous defibrillators.

Which companies have invested in Newpace?

Newpace has received funding from investors including Net Capital Ventures and BioStar Capital.